enVVeno Medical Corporation (NVNO) AI Stock Analysis

enVVeno Medical Corporation is a medical device company developing bioprosthetic tissue-based solutions to treat venous diseases. Its lead product candidate is the VenoValve, a surgical implant placed in the femoral vein to treat severe deep venous chronic venous insufficiency by restoring one-way blood flow in the leg. Founded in 1999 as Hancock Jaffe Laboratories, Inc. and based in Irvine, California, the company rebranded to focus on venous health. Beyond the VenoValve, enVVeno develops a portfolio of bioprosthetic tissue technologies aimed at establishing new standards of care in vascular surgery and addressing unmet medical needs.

enVVeno has transitioned from minimal early commercial sales to a development-stage profile with $0 in trailing twelve month revenue through June 30, 2026. Between FY2016 and FY2019, revenue contracted at a compound annual rate of -65.9%, declining from $785,912 in FY2016 to $422,111 in FY2017, $186,552 in FY2018, and $31,243 in FY2019. Annual net losses were -$5.9M in FY2016, -$7.8M in FY2017, -$13.0M in FY2018, and -$7.6M in FY2019. Over that span, research and development spending rose from $649,736 in FY2017 to $2.2M in FY2019. TTM diluted earnings per share stood at -$24.99, with a return on equity of -58.5%.

As of June 30, 2026, enVVeno held $21.5M in cash and short-term investments against total debt of $505,000, resulting in net cash of $21.0M. Shareholders' equity was $20.7M and total assets stood at $22.7M. The company maintains short-term liquidity with a current ratio of 11.70 and a debt-to-equity ratio of 0.02. In FY2025, capital expenditures were $5,000. Historically, free cash flow was negative, including -$6.3M in FY2019, and the share count expanded by 7273.6% over a five-year period to fund operations.

enVVeno trades at an enterprise value of -$15.0M and a market capitalization of $5.2M. The stock trades at a price-to-book multiple of 0.3x, while its price-to-sales ratio is 216.9x and EV-to-revenue is 274.9x, compared to a median price-to-sales ratio of 4.1x for its US-listed Healthcare peers. The peer group median EV-to-EBITDA stands at 12.0x and trailing P/E at 24.6x. Over the past year, NVNO fell 72.9%, trailing the S&P 500 return of 16.8%. Over five years, the stock dropped 97.9% compared to an 83.0% gain for the S&P 500.

Wall Street coverage includes 1 Strong Buy rating, with 0 Buy, 0 Hold, and 0 Sell ratings. The mean analyst price target is $30.00, representing an upside of 301.6% above the last close of $7.47. For the fiscal year ending December 31, 2026, the consensus expects EPS of -$16.19 on $0 in revenue. For the following fiscal year, 1 analyst projects an EPS of -$6.22, reflecting an estimated EPS growth of 61.6%, alongside $0 in revenue. Over the last four quarters, enVVeno beat EPS estimates 2 times. The next earnings date is October 30, 2026.

This page is an AI-written research summary of enVVeno Medical Corporation (NVNO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NVNO income statement, NVNO balance sheet, NVNO key metrics, NVNO analyst forecast, NVNO chart. See the NVNO stock overview for the latest quote and news.